Feed BTAI
BT

BioXcel Therapeutics, Inc.

BTAI · NASDAQ

$0.07 -18.79% (-$0.02)
1M -90.28%
Market Cap $2.28M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9
Valuation
57 /100
Fair
P/S 3.08x
P/E N/A
P/FFO N/A
Growth
100 /100
Growing
Rev. growth 19.63%
EPS growth N/A
Book val. growth N/A
Profitability
18 /100
Weak
Gross margin 45.28%
FCF margin 6,860.38%
Net margin 9,549.86%
Quality
58 /100
Average
ROIC 1,144.58%
Asset turnover 0.03x
ROA 246.05%
Debt
0 /100
High
Current ratio 0.21x
Int. coverage -3.11x
Debt/Equity N/A
Stability
19 /100
Unstable
Beta 0.29x
Profitable years 0
Rev. volatility 170.96%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o BTAI
Online

O podjetju

BioXcel Therapeutics, Inc. (BTAI) is a biotechnology company that focuses on researching and developing new therapeutic approaches using artificial intelligence and data analysis. The company leverages advanced technologies and algorithms to identify and develop drugs for various diseases, including neurological and psychiatric disorders. With an innovative approach to drug development and treatment using artificial intelligence, the shares of BioXcel Therapeutics, Inc. (BTAI) may represent an intriguing investment opportunity for investors interested in biotechnology and medical research.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Vimal D. Mehta

Employees

29

Headquarters

New Haven

Prihajajoči dogodki

11 NOV.

Earnings

Upcoming earnings report

50d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.